07/04/2026 Climb Bio announced FDA Fast Track Designation for budoprutug for the treatment of pMN Climb Bio announced FDA Fast Track Designation for budoprutug for the treatment of pMN ( Ref ) Climb Bio announced that the US FDA had granted Fast Track Designation to budoprutug (anti-CD19 mAb) for the treatment of primary membranous nephropathy (pMN) Brudoprutug was being studied in Phase 2 patinets with pMN  The company anticipated initial data from Phase 2 study in H2 2026